Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New RSV vaccine immunogenicity improved with protein engineering

Publish date:: August 8, 2019

Key clinical point: New respiratory syncytial virus vaccine candidate DS-Cav1 has greater immunogenicity than previous candidates.

Major finding: Epitope-neutralizing activity is 5-10 times greater 12 weeks after baseline with a 50 mcg or 150 mcg with and without alum adjuvant.

Study details: The findings are based on a prespecified interim analysis of 90 healthy adult participants in a phase 1, randomized, trial of DS-Cav1.

Disclosures: The research was funded by the National Institutes of Health and the Bill & Melinda Gates Foundation. Several authors are inventors on patents for stabilizing the RSV F protein.

Citation:

Crank MC et al. Science. 2019;365(6452):505-9.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Infectious Diseases

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

Vaccine-preventable infection risk high for pediatric hematopoietic cell transplantation recipients,

Three genes could predict congenital Zika infection susceptibility,

Obesity, hypoxia predict severity in children with COVID-19,

Two consecutive negative FUBC results clear S. aureus bacteremia,